Dr. Hoos Describes Ipilimumab and Future Immunotherapies
Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses ipilimumab (Yervoy) and how it is a first-in-class agent that enhances activation of T cells. He elaborates that Bristol-Myers Squibb plans to build upon this success with their new drug the anti-PD-1 agent MDX-1106.
Related Videos
Related Content
